9I果冻制作厂官网

目录产物 » LAG-3/CD223, hFc, Human
LAG-3 (CD223) Fc Chimera, Human

LAG-3 (CD223) Fc Chimera, Human

LAG-3 (CD223) Fc Chimera, Human

Immobilized FGL-1-His (LC13SE1012) at 2 μg/ml (100 μl/well) can bind Human LAG-3 (CD223) Fc Chimera with EC50=0.306 ?g/ml when detected by Mouse Anti–Human IgG FC-HRP. Background was subtracted from data points before curve fitting.

LAG-3 (CD223) Fc Chimera, Human

Lymphocyte activation gene-3 (LAG-3), also known as CD223, is a cell-surface 70kDa molecule belong to Ig superfamily with diverse biologic effects on T cell function. LAG-3 is a CD4 homolog originally cloned in 1990. The gene for LAG-3 lies adjacent to the gene for CD4 on human chromosome 12 (12p13) and is approximately 20% identical to the CD4 gene. human LAG-3 shares 70%, 67%, 76%, and 73% aa sequence identity with mouse, rat, porcine, and bovine LAG-3, respectively. LAG-3 is expressed on B cells, NK cells, tumor-infiltrating lymphocytes, and a subset of T cells. LAG-3 was relatively overexpressed on transgenic T cells rendered anergic in vivo by encounter with cognate self-antigen. LAG-3 negatively regulates murine T cell activation and homeostasis. LAG-3 activates antigen-presenting cells through MHC class II signaling, leading to increased antigen-specific T-cell responses in vivo. Blocking or knocking out LAG-3 in neuronal cultures or in animals mitigated the transmission of α-synuclein between neurons, and dampened accumulation as well as toxic effects of the fibrils on motor function. Anti-LAG3 antibodies are already being tested as cancer treatments, it could also make a useful therapeutic target to treat Parkinson’s and other synucleinopathies.
Z03422
¥1760

联系我们
Species Human
Protein Construction
LAG-3/CD223 (Leu23-Leu450)
Accession # P18627
hFc
N-term C-term
Purity > 95% as analyzed by SDS-PAGE
Endotoxin Level < 1 EU/μg of protein by gel clotting method
Biological Activity Immobilized FGL-1-His (LC13SE1012) at 2.0 μg/ml (100 μl/well) can bind LAG-3/CD223, hFc, Human with EC50 = 0.306 ?g/ml when detected by Mouse Anti–Human IgG FC-HRP.
Expression System HEK 293
Apparent Molecular Weight ~86.0 kDa, on SDS-PAGE under reducing conditions.
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH?O or PBS up to 100 μg/ml.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

  • LAG-3 (CD223) Fc Chimera, Human
  • LAG-3 (CD223) Fc Chimera, Human

  • LAG-3 (CD223) Fc Chimera, Human
  • LAG-3 (CD223) Fc Chimera, Human

  • LAG-3 (CD223) Fc Chimera, Human
  • LAG-3 (CD223) Fc Chimera, Human

    Immobilized FGL-1-His (LC13SE1012) at 2 μg/ml (100 μl/well) can bind Human LAG-3 (CD223) Fc Chimera with EC50=0.306 ?g/ml when detected by Mouse Anti–Human IgG FC-HRP. Background was subtracted from data points before curve fitting.


Target Background Lymphocyte activation gene-3 (LAG-3), also known as CD223, is a cell-surface 70kDa molecule belong to Ig superfamily with diverse biologic effects on T cell function. LAG-3 is a CD4 homolog originally cloned in 1990. The gene for LAG-3 lies adjacent to the gene for CD4 on human chromosome 12 (12p13) and is approximately 20% identical to the CD4 gene. human LAG-3 shares 70%, 67%, 76%, and 73% aa sequence identity with mouse, rat, porcine, and bovine LAG-3, respectively. LAG-3 is expressed on B cells, NK cells, tumor-infiltrating lymphocytes, and a subset of T cells. LAG-3 was relatively overexpressed on transgenic T cells rendered anergic in vivo by encounter with cognate self-antigen. LAG-3 negatively regulates murine T cell activation and homeostasis. LAG-3 activates antigen-presenting cells through MHC class II signaling, leading to increased antigen-specific T-cell responses in vivo. Blocking or knocking out LAG-3 in neuronal cultures or in animals mitigated the transmission of α-synuclein between neurons, and dampened accumulation as well as toxic effects of the fibrils on motor function. Anti-LAG3 antibodies are already being tested as cancer treatments, it could also make a useful therapeutic target to treat Parkinson’s and other synucleinopathies.
Synonyms LAG3; CD223; FDC; LAG-3

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


喜欢新升级的网站吗?

讨厌

不喜欢

一般

喜欢

非常喜欢

*